Bioassay Directed Isolation and Biological Evaluation of Compounds Isolated from Rubus fairholmianus Gard.

Blassan Plackal George,1 Parimelazhagan Thangaraj,1 Cheruthazhakkatt Sulaiman,2 Shanmughavel Piramanayagam,3 and Sathish Kumar Ramaswamy3

1 Bioprospecting Laboratory, Department of Botany, School of Life Sciences, Bharathiar University, Coimbatore, Tamil Nadu 641 046, India
2 Phytochemistry Division, Centre for Medicinal Plants Research, Arya Vaidya Sala, Kottakkal 67 6 503, India
3 Department of Bioinformatics, Bharathiar University, Coimbatore, Tamil Nadu 641 046, India

Correspondence should be addressed to Parimelazhagan Thangaraj; drparimel@gmail.com

Received 13 February 2014; Revised 27 March 2014; Accepted 8 April 2014; Published 1 September 2014

Academic Editor: Kuo-Chen Chou

Copyright © 2014 Blassan Plackal George et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The in vitro and in silico analysis of Rubus fairholmianus acetone extract for antioxidant, antiproliferative, and anti-inflammatory activity led to the isolation of six compounds. Amongst all the six isolated compounds tested, 1-(2-hydroxyphenyl)-4-methylpentan-1-one (compound 1) and 2-[(3-methylbutoxy) carbonyl] benzoic acid (compound 2) were found to be more active in inhibiting BRCA and COX target proteins, which also showed the better results for DPPH and ABTS radical scavenging assays. The promising results of this investigation emphasize the importance of using R. fairholmianus in the treatment of radical generated disorders mainly cancer and other inflammatory diseases.

1. Introduction

The genus Rubus is very diverse, includes over 750 species in 12 subgenera, and is found on all continents except Antarctica [1]. Due to useful ethnomedicinal and pharmacological properties, Rubus species has been used in folk medicine [2]. The leaf extract of R. fairholmianus (R. moluccanus L.) collected in the early morning has been used by Koch-Rajbongshi and Rangia tribes to reduce headache by [3]. The leaves have been reported to possess insecticidal properties; fruits are edible and stimulant [4]. The total phenolic content and antioxidant and analgesic potential of R. fairholmianus extracts have been evaluated by George et al. [5]. R. fairholmianus root acetone extract showed significant anti-inflammatory and wound healing properties which may be due to the presence of analogues of quercetin and other related polyphenolic compounds [6].

The literature showed that the berries (Rubus sp.) of Rosaceae family have been reported for their strong antioxidant and pharmacological properties [5–9] and various bioactive free radical scavenging compounds were isolated [10–14]. Berry fruits are characterized by a high content and wide diversity of bioactive compounds such as phenolic compounds, organic acids, tannins, anthocyanins, and flavonoids [15]. Oxidative stress is caused by an imbalance between antioxidant systems and the production of oxidants, which is associated with many diseases like cancers, cardiovascular diseases, and inflammation related disorders [16]. A large number of naturally occurring antioxidant compounds have been identified from different plant sources, as free radical or active oxygen scavengers [17, 18]. Antioxidants protect organisms against free radicals and they are vital to neutralize the destruction caused by the radicals with a sufficient supply of antioxidants [19].

Molecular docking is an approach to help researchers to screen a large set of small molecules by orienting and scoring them in the binding site of target proteins. Top ranked compounds have been tested in vitro and further they may become lead compounds for drug development. The Glide
score, number of H-bonds, distance of bonds, interacted protein residues, and ligand atom were observed from docking studies. This docking study helps us in understanding the binding mode of the isolated compounds with the target proteins.

In the present scenario the antioxidant researchers are mainly focusing on the identification and isolation of new natural antioxidant compounds from different plants species, since it can protect the human body from various free radical generated disorders. A survey of literature revealed that the phytochemical aspects of this plant have not been evaluated. This study aimed to investigate the antioxidant activities of different extracts of *R. fairholmianus*. This study focuses on the isolation and identification of bioactive antioxidant compounds from *R. fairholmianus* through chromatographic techniques based on the activity guided fractionation of the root acetone extract. The isolated compounds then checked for its antioxidant potential. Further, we adopted docking studies to identify inhibiting activity of the compounds against BRACA and COX proteins.

2. Materials and Methods

2.1. Plant Collection and Extraction. The fresh plant parts of *R. fairholmianus* were collected from Marayoor Shola forest, Kerala, India, during the month of September 2010. The collected plant material was identified and authenticated by (Voucher specimen number BSI/SRC/5/23/2010-11/Tech. 1657) Botanical Survey of India, Southern Circle, Coimbatore, Tamil Nadu. The roots were extracted successively using acetone in a soxhlet apparatus for 72 hours. The extract was concentrated to dryness under reduced pressure in a rotary evaporator.

2.2. Determination of In Vitro Antioxidant Activities. The different fractions and isolated compounds from root acetone extracts of *R. fairholmianus* were analyzed for their antioxidant activity using DPPH assay and ABTS assay.

2.2.1. DPPH Radical Scavenging Activity. The DPPH assay was done as per the method described by Blois [20]. Negative control was prepared by adding 100 μL of methanol in 5 mL of 0.1 mM methanolic solution of DPPH*. The tubes were allowed to stand for 20 minutes at 27°C. Radical scavenging activity of the samples was expressed as IC₅₀ which is the concentration of the sample required to inhibit 50% of DPPH* concentration.

2.2.2. Trolox Equivalent Antioxidant Capacity (TEAC) Assay. The total antioxidant activity was measured by ABTS radical cation decolourization assay according to Re et al. [21]. Triplicate determinations were made at each dilution of the standard, and the percentage inhibition was calculated against the blank (ethanol) with an absorbance at 734 nm and then was plotted as a function of Trolox concentration. The unit of total antioxidant activity (TAA) is defined as the concentration of Trolox having equivalent antioxidant activity expressed as μM/g sample extracts.

2.3. Chromatographic Separation of the Root Acetone Extract. Based on the *in vitro* antioxidant studies, RFRA (*R. fairholmianus* root acetone) showed maximum antioxidant activity and it was selected for the further isolation of phytoconstituents. The preliminary screening was done using thin layer chromatography by toluene: ethyl acetate: acetic acid (6:3:0.5) as mobile phase. The extract (50 g) was adsorbed on activated silica (230–400 mesh). The column (90 × 5 cm) was packed with activated silica gel (230–400 mesh) in toluene and it was eluted with 400 mL of each of different solvents such as toluene (100%), toluene: ethyl acetate (9:1, 7:3, 6:4, 5:5, 4:6, 2:8), ethyl acetate: chloroform (9:1, 7:3, 5:5, 3:7, 1:9), chloroform: methanol (8:2, 6:4, 5:5, 4:6), diethyl ether (100%), ethanol (100%), methanol (100%), acetic acid (2%), and acetone (100%). A total of 183 fractions were collected and the fractions with similar chemical profiles were pooled based on TLC analysis. Based on the TLC, the fractions with similar banding pattern were clubbed and 16 fractions were obtained. The various fractions such as F1 (34–37), F2 (38–54), F3 (55–58), F4 (59–72), F5 (76–80), F6 (84–88), F7 (89–110), F8 (111–116), F9 (121–126), F10 (132–136), F11 (137–141), F12 (142), F13 (143–147), F14 (148–151), F15 (159–162), and F16 (163–183) were subjected to antioxidant studies. The most active fractions such as F5, F7, F9, and F16 were selected for further isolation process.

The 4 active fractions further yielded 6 subfractions: methanol and ethyl acetate subfractions of F5 (F5M and F5EA), chloroform subfractions of F7 and F9 (F7C and F9C), and methanol and diethyl ether subfractions of 16 (F16M and F16DE). All these fractions were analysed by TLC, HPLC, and so forth.

2.4. Purification of Isolated Compounds. The isolated compounds were purified by semipreparative HPLC and preparative HPLC. The bands visualized under UV at 254 nm and 280–400 nm were scrapped out and dissolved in respective solvents. The time based collection was performed using preparative fraction collector on Agilent 1200 high pressure liquid chromatographic system equipped with prep pump, a rheodyne injector, and diode array detector in combination with Chem32, Chemstation software. C18-scalar (5 μm, 4.6 × 150 mm) Agilent column was used for separation with a binary gradient elution. Mobile phase: 0.1% acetic acid in acetonitrile (A): methanol: water (60:40: B) 0–2: 70% A, 2–5 60% A, 5–10: 50% A, 10–20 70% A. The flow rate was maintained as 15 mL/minute.

2.5. Characterization of Isolated Compounds

2.5.1. UV Spectroscopy. The UV-visible spectrum of the isolated compound in HPLC grade methanol was recorded using a Shimadzu 160 A UV-visible spectrophotometer at a range of 280–400 nm.

2.5.2. Fourier Transform Infrared Spectrometry (FTIR). The FTIR spectrum was recorded using a Nicolet 5700 (Thermo electron, Madison, WI, USA) spectrometer at room temperature. The bioactive compound was dissolved in dimethyl
sulfoxide (DMSO) and scanned in the range of 4000-400 cm\(^{-1}\).

2.5.3. Nuclear Magnetic Resonance Spectroscopy (NMR). NMR spectra were recorded on a Bruker DRX 500 NMR instrument operating at 500 MHz for \(^1\)H and 125 MHz for \(^{13}\)C at room temperature. A region from 0 to 12 ppm for \(^1\)H and 0 to 200 ppm for \(^{13}\)C was employed. Signals were referred to as the internal standard tetramethylsilane (TMS). About 10 mg of the sample dissolved in 0.5 mL of CDCl\(_3\) was used for recording the spectra.

2.5.4. Mass Spectrometry. LC-ESI-MS analysis was conducted on Agilent 6520 accurate mass Q-TOF LC/MS coupled with Agilent LC 1200 equipped with Extend-C18 column of 1.8 \(\mu\)m, 2.1 \(\times\) 50 mm. Gradient elution was performed with methanol (solvent A, 70%) and 0.1% formic acid (solvent B, 30%) at a constant flow rate of 0.3 mL/min. Column temperature was maintained at 30\(^\circ\)C. The MS analysis was performed using ESI in the negative mode. The conditions for mass spectrometry were as follows: drying gas (nitrogen) flow 5 L/min; nebulizer pressure 50 psig; drying gas temperature 325\(^\circ\)C; capillary voltage +3000 V; fragmentor voltage 250 V; Oct Rf Vpp 750 V.

2.6. Molecular Docking of Bioactive Compounds against BRCA and COX Proteins. Molecular docking has become an increasingly important tool for drug discovery. It is a useful vehicle for investigating the interaction of a protein receptor with its ligand and revealing their binding mechanism as demonstrated by a series of studies [22–27]. We have employed flexible docking strategies in this study to identify the most suitable ligand binding sites in the BRCA and COX target proteins. Flexible molecular docking operations require no prior knowledge of the ligand conformation and such an approach becomes necessary if there is no useful information on the conformation of a particular ligand.

2.6.1. Protein Retrieval and Preparation. Three-dimensional structures of BRCA1, BRCA2, COX-1, and COX-2 proteins were obtained from PDB database (PDB id: 1T15, 3EU7, 1EQH, 3LN1) (PDB http://www.rcsb.org/). The retrieved protein has been prepared for docking using Protein Preparation Wizard [28]. Finally the grid was generated for the prepared proteins.

2.6.2. Inhibitory Molecules Retrieval and Preparation. Inhibitory molecules were retrieved from PubChem database in 3D SDF format. The compounds such as cyclophosphamide, letrozole, doxorubicin, paclitaxel, and tamoxifen (PubChem id: CID 2907, CID 3902, CID 31703, CID 36314, CID 2733526) are the commercially available standard drugs for the treatment of cancer; diclofenac, indomethacin, paracetamol, aspirin, and morphine (PubChem id: CID 3033, CID 3715, CID 1983, CID 2244, CID 5288826) are the NSAIDs used commonly for the treatment of inflammation related diseases. About 6 compounds such as 3( imino methyl)-2,4-dimethyl phenol, isopentyl benzoate or 3-methylpentyl benzoate, 4-methylpentyl benzoate, 2- (isopentenyloxycarbonyl) benzoic acid, 2-(5-methylhexyl) benzoic acid, and 1-(2-hydroxyphenyl)-4-methyl pentan-1-one isolated from R. fairholmianus root acetone extract were screened for their inhibitory activity against BRCA and COX proteins. Retrieved molecules were prepared for docking using LigPrep module [29]. Finally the prepared compounds were used for docking with BRCA and COX proteins.

2.6.3. Molecular Docking of Target Proteins with Inhibitory Molecules. The docking was performed using Glide module [30–32], through blind docking approach in which commercially available drugs and newly isolated compounds were docked against BRCA and COX proteins. Docked complex was examined with an emphasis on visual rather than numerical appraisal, so we used XP visualizer.

2.7. Statistical Analysis. All the values are expressed as mean ± SEM. The values are analyzed using one-way ANOVA and the significance of the difference between means was determined by Duncan’s, Tukey Kramer multiple comparisons using SPSS.

3. Results and Discussion

3.1. In Vitro Antioxidant Activity. Figure 1 schematically represents the isolation procedure of bioactive compounds; all the compounds reported in this study were isolated for the first time from R. fairholmianus. The antioxidant activity of different fractions and isolated compounds was evaluated using DPPH and ABTS radical scavenging assays. The results are given in Table 1. Among the different fractions, F9 showed highest scavenging activity against DPPH (IC\(_{50}\) value 3.61). The IC\(_{50}\) values of the isolated compounds ranged between 12.35 and 3.23 \(\mu\)g/mL. Compound 1 (1-(2-hydroxyphenyl)-4-methylpentan-1-one) showed maximum DPPH radical scavenging activity with IC\(_{50}\) 3.23 \(\mu\)g/mL. The ABTS radical scavenging activities of the fractions ranged between 1140.74 and 4974.72 \(\mu\)M TE/g. The isolated compounds also showed commendable ABTS radical scavenging activities, with highest value for 2-[(3-methylbutoxy) carbonyl] benzoic acid (compound 2) (923.20 \(\mu\)M TE/g).

No previous reports are available on DPPH radical scavenging activity of this species. The phenolic compounds in berries have been well characterized as natural antioxidants, which are believed to play a major role in certain health benefits. The naturally occurring phenolic antioxidants encompass a diverse range of chemical classes that protect against the damage caused by ROS to DNA and membrane and cellular components [33]. The strong antioxidant activities of R. fairholmianus may be due to the phenolic compounds. Previously, Vadivelan et al. [34] reported the antioxidant properties of R. ellipticus root. The root methanol extracts showed strongest radical scavenging activity (IC\(_{50}\): 12.2 \(\mu\)g/mL against DPPH\(^*\) and (IC\(_{50}\): 2.5 \(\mu\)g/mL against ABTS radical. Comparing these results, the DPPH and ABTS radical scavenging activities of the isolated column fractions
Rubus fairholmianus root powder

Petroleum ether

Chloroform

Acetone

MeOH

Silica gel column chromatography I

(227 fractions eluted)

Out of 20 pooled fractions, F5, F7, F9, and F16 are found to be more active

F5(76–80) ethyl acetate: chloroform (9:1) eluted fractions

F7(89–110) ethyl acetate: chloroform (7:3, 5:5, 3:7) eluted fractions

F9(121–126) ethyl acetate: chloroform (9:1) eluted fractions

F16(163–183) diethyl ether (100%), chloroform: methanol (5:5, 4:6) eluted fractions

Eluted fractions

Compound 1

Compounds 2 and 3

Compound 4

Diethyl ether (100%) dissolved fractions

Compound 5

Methanol dissolved F16 fraction

Silica gel column chromatography II

(33 fractions eluted)

F(13–32) chloroform: isopropyl alcohol (7:3), chloroform: dimethyl ether: methanol (6:3:1) and chloroform: tetrahydroxy furan (7:3) eluted fractions

Compound 6

Figure 1: Schematic representation showing the isolation procedure of bioactive compounds from R. fairholmianus.

and compounds of R. fairholmianus are highly significant and are almost equivalent and more than that of the standards. The DPPH radical scavenging activity of an allied species R. sanctus has also been reported, which was found to scavenge the DPPH radical by 83.27% compared to vitamin C and BHT (97.15 and 96.47%) [35]. Comparing the literatures, the isolated compounds and fractions of R. fairholmianus root acetone extract have a commendable antioxidant activity in the tested assays.

3.2. Identification of the Isolated Bioactive Compounds. The structure and molecular formula of the isolated compounds are shown in Table 2.

**Compound 1.** The fraction F5 yielded yellowish white amorphous solid (10.2 mg) after recrystallization on methanol. UV (methanol) λmax nm: 280; IR (KBR) cm⁻¹: 3438.53, 1729.41, 1614.15, 1279.43. ¹H NMR (CDCl₃) δ 7.73, 7.73, 7.54, 7.53, 4.8, 4.3, 1.55, 2.07, 0.98, 0.99. ¹³C NMR: δ 169.43, 160.01, 134.16, 132.66, 130.61, 122.11, 73.56, 43.56, 31.46, 29.49, 20.91. MS (m/z) [M-H]: 191.98. The compound was identified as 1-(2-hydroxy phenyl)-4-methyl pentan-1-one.

**Compound 2.** Fraction F7 presented brownish crystalline solid (8.46 mg) on evaporation. UV (methanol) λmax nm: 290. IR (KBR) cm⁻¹: 3430.90, 2926.30, 1725.88, 1278.61. ¹H NMR (CDCl₃): δ 8.03, 7.92, 7.89, 7.71, 7.54, 7.51, 4.30, 4.29, 2.05, 2.04, 1.73, 1.70, 0.98. ¹³C NMR: δ 167.71, 125.69, 128.84, 66.55. The molecular formula of this compound was established based on the mass spectrum MS (m/z) [M-H]: 235.12. The structure was confirmed as cis-2-(isopentyloxycarbonyl) benzoic acid.

**Compound 3.** [2-(5-Methylhexyl) benzoic acid] 6.79 mg, white amorphous solid recrystallised on evaporation of chloroform from fraction 7 (F7). UV (methanol) λmax nm: 290; IR (KBR) cm⁻¹: 3427.20, 2926.85, 1728.35, 1626.05, 1281.20 and 1127.82. ¹H NMR (CDCl₃): δ 7.71, 7.70, 7.69, 7.53, 7.52, 7.51, 7.50, 4.24, 4.23, 4.22, 4.20, 4.19, 4.18. ¹³C NMR: δ 167.73, 142.39, 132.49, 132.36, 130.88, 130.86, 128.80, 66.19, 38.76, 36.68, 35.50, 32.50, 28.80. MS (m/z) [M-H]: 219.19.

**Compound 4.** [4-Methylpentyl benzoate] 6.18 mg, white amorphous crystals from the diethyl ether fraction of F9. UV (methanol) λmax nm: 280; IR (KBR) cm⁻¹: 2958.00, 1727.47, 1462.12, 1280.11 and 1125.88. ¹H NMR (CDCl₃): δ 7.71, 7.70,
Table 1: DPPH and ABTS radical scavenging activities of fractions and compounds of *R. fairholmianus*.

| Fractions and compounds | DPPH radical scavenging activity (IC₅₀: μg/mL) | ABTS radical cation scavenging activity (μM Trolox equivalents/g extract) |
|-------------------------|-----------------------------------------------|---------------------------------------------------------------------|
| 1                       | 14.73                                         | 2240.99 ± 32.55                                                     |
| 2                       | 17.95                                         | 1363.49 ± 23.38                                                     |
| 3                       | 18.70                                         | 3749.60 ± 5.85                                                      |
| 4                       | 20.31                                         | 3074.61 ± 35.56                                                     |
| 5                       | 7.16                                          | 3496.48 ± 51.96                                                     |
| 6                       | 18.01                                         | 4478.60 ± 35.56                                                     |
| 7                       | 9.55                                          | 3374.98 ± 23.38                                                     |
| 8                       | 25.56                                         | 2335.49 ± 40.92                                                     |
| 9                       | 3.61                                          | 4650.72 ± 15.47                                                     |
| 10                      | 15.36                                         | 4377.35 ± 11.69                                                     |
| 11                      | 21.97                                         | 2234.24 ± 5.85                                                      |
| 12                      | 27.79                                         | 1140.74 ± 30.93                                                     |
| 13                      | 24.63                                         | 4765.47 ± 47.85                                                     |
| 14                      | 16.39                                         | 4974.72 ± 45.66                                                     |
| 15                      | 13.41                                         | 3860.98 ± 42.15                                                     |
| Compound 1              | 3.23                                          | 5344.45 ± 24.94                                                     |
| Compound 2              | 5.09                                          | 9233.20 ± 54.32                                                     |
| Compound 3              | 10.76                                         | 6421.23 ± 84.46                                                     |
| Compound 4              | 8.57                                          | 8754.78 ± 42.29                                                     |
| Compound 5              | 12.35                                         | 5656.32 ± 38.53                                                     |
| Compound 6              | 9.43                                          | 7455.54 ± 62.98                                                     |
| Butylated hydroxy toluene (BHT) | 13.18                                      | —                                                                   |
| Butylated hydroxy anisole (BHA) | 4.88                                        | —                                                                   |
| Rutin                   | 5.81                                          | —                                                                   |
| Quercetin               | 4.12                                          | —                                                                   |

Values are mean of triplicate determination (*n* = 3) ± standard deviation. Statistically significant at *P* < 0.05 where a > b > c > d.

There are many reports available on the phytochemical characterization and activity guided studies of the related species of *Rubus*. Most of the compounds isolated from the *Rubus* species belong to the cyanidin type compounds, anthocyanins, and tannins. Ruiz et al. [36] reported the presence of total anthocyanins (0.34–0.92 μmol/g), monomeric anthocyanins (0.31–1.16 μmol/g), and cyanidin-3-sambubioside in the fruits of *R. geoides*. Kubota et al. [37] isolated and purified the anthocyanins: cyanidin-3-O-glucoside and pelargonidin-3-O-glucoside from *R. croceacanthus* fruits and pelargonidin-3-O-glucoside and pelargonidin-3-Orutinoside from *R. sieboldii* fruits. Porter and coworkers [38] reported the minor flavonoid components in *R. idaeus*. Estupiñan et al. [39], Vasco et al. [40], Garzón et al. [41], Mertz et al. [11], Kim et al. [42], Ku and Mun [43], Bae et al. [44], Deighton et al. [45], Wyzgoski et al. [46], Dossett et al. [47], Ling et al. [48], Dossett et al. [49], Tulio et al. [50], and Tian et al. [51] reported the presence of cyanidin-3-glucoside and cyanidin-3-rutinoside, cyanidin-3-sambubioside, cyanidin-3-xyllosylrutinoside, pelargonidin-3-glucoside, and pelargonidin-3-rutinoside, cyanidin glycoside, lambertianin C and sanguin H-6, and 2 ellagitannins in various *Rubus* species. Bowen-Forbes et al. [52] reported the presence of...
Table 2: Structure of the isolated compounds.

| Sl. No. | Name                                  | Structure | Molecular formula | Molecular weight |
|--------|---------------------------------------|-----------|-------------------|------------------|
| 1      | 1-(2-Hydroxyphenyl)-4-methylpentan-1-one | ![Structure](#) | C₁₁H₁₆O₂           | 192.25           |
| 2      | 2-[(3-Methylbutoxy)carbonyl] benzoic acid | ![Structure](#) | C₁₃H₁₆O₄           | 472.53           |
| 3      | 2-(5-Methylhexyl) benzoic acid         | ![Structure](#) | C₁₄H₂₀O₂           | 220.31           |
| 4      | 4-Methylpentyl benzoate                | ![Structure](#) | C₁₃H₁₈O₂           | 206.28           |
| 5      | 3-(Iminomethyl)-2,4-dimethylphenol     | ![Structure](#) | C₉H₁₁NO            | 149.19           |
| 6      | 3-Methylbutyl benzoate                 | ![Structure](#) | C₁₂H₁₆O₂           | 192.25           |

eight hydroxyursane type compounds: euscaphic acid, 1-b-hydroxyeuscaphic acid, hyptatic acid B, 19α-hydroxyasiatic acid, trachelosperogenin, 4-epi-nigaichigoside F₁, nigaichigoside F₁, and trachelosperoside B-1 in the ethyl acetate extract of *R. rosifolius* fruits.

3.3. Molecular Docking of Isolated Compounds against BRCA and COX Proteins. Isolated compounds and standard drugs for cancer treatment were docked against BRCA1. The docking score and hydrogen bond interactions of the compounds are showed in Table 3. 1-(2-Hydroxyphenyl)-4-methylpentan-1-one (G score: −4.7) has high binding with active site of BRCA1 protein followed by 2-[(3-methylbutoxy)carbonyl] benzoic acid (G score: −3.86). The standard drugs such as doxorubicin and letrozole also showed strong binding affinity (G score: −4.82 and −4.18, resp.). The docking results of BRCA1 revealed that the mode of molecular interactions of the isolated compounds and standard drugs was almost similar (Figure 2). Meanwhile, 1-(2-hydroxyphenyl)-4-methylpentan-1-one and 4-methylpentyl benzoate also showed fairly good binding affinities towards the target protein BRCA2 with a G score of −4.5 and −3.8, respectively. 2-[(3-Methylbutoxy)carbonyl] benzoic acid also docked with a moderate G score (−3.1); the binding affinities were
found to be more than that of the standards letrazole and paclitaxel (G score: −3.0 and −2.9). The standard drug doxorubicin showed a G score of −11.1 followed by tamoxifen (G score: −5.9). Among the 6 isolated compounds, only three compounds were found to have good docking with target protein. The molecular interaction and docking score of the compounds are shown in Table 4 and Figure 3. The molecular docking results showed that the isolated compound 1-(2-hydroxyphenyl)-4-methylpentan-1-one is highly significant in binding (G score: −4.7) and formed three hydrogen bonds against SER 6: H (HG), GLY 1656: (H) H, and LYS 1702 (H) HZ2 residues of BRCA1. The residues involved in binding were more or less similar with that of standard drugs. The docking score of 2-[(3-methylbutoxy)carbonyl] benzoic acid, 4-methylpentyl benzoate, 2-(5-methylhexyl) benzoic acid, 3-(iminomethyl)-2,4-dimethylphenol, and 3-methylbutyl benzoate compounds ranged between −3.4 and −3.83 and the docking score of the standard drugs falls between −2.0 and −4.82. Docking score and H-bond interaction of all 6 isolated compounds were closely related to standard drugs. The docking results of BRCA2 with the isolated compounds 1-(2-hydroxyphenyl)-4-methylpentan-1-one and 4-methylpentyl benzoate are significant. 1-(2-Hydroxyphenyl)-4-methylpentan-1-one formed three hydrogen bonds with the ALA 874: (O) O, ALA874: (H) H, and GLY1166: (H) H residues of BRCA2 protein and 4-methylpentyl benzoate formed 2 hydrogen bonds with the ALA 1063: (H) H and LYS 1062 (H) HZ2 residues of BRCA2. Some of the binding residues were common in both standard drugs and the isolated compounds. The G score of isolated compounds ranged between −4.5 and −3.1, whereas the standard drugs were in between −11.1 and −3.2. BRCA1 and BRCA2 predispose individuals to breast, ovarian, and other cancers. These proteins are required for the maintenance of genetic stability and have function in DNA damage [53].

Previously, Raja et al. [54] studied the docking analysis of mangrove-derived compounds and revealed that, among six compounds triterpenoid, stigma sterol, and pyrethrin were efficient in destroying BRCA1. Saravanakumar and coworkers [55] proposed the docking of fungal metabolites against BRCA1. The docking score of phthalic acid was lowest (−13.71 kcal/mol) followed by 2,3-dihydro-1H-inden-2-yl acetate and 3-methylcyclopentan-1-ol having the value of −11.1 and −9.08, respectively. However, there is no report on the docking of isolated compounds from R. fairholmianus against BRCA proteins. So the information gained from this study will be useful for further development of novel breast cancer inhibitors.

### Table 3: Docking score and H-bond interaction of ligands with BRCA1 protein (1T15).

| Ligand | G score | Number of H-bonds | Distance (Å) | Protein atom | Ligand atom |
|--------|---------|--------------------|-------------|--------------|-------------|
| Doxorubicin | −4.82 | 5 | 2.449 | SER 6: H (HG) | O |
| | | | 2.418 | LEU1657: (O) O | H |
| | | | 2.470 | ASN1678: (O) O | H |
| | | | 2.203 | PRO9: (O) O | H |
| | | | 2.013 | LYS1702: (H) HZ2 | O |
| Letrozole | −4.18 | 2 | 2.109 | GLY 1656, (H) H | N |
| | | | 2.056 | SER 6: H (HG) | N |
| Cyclophosphamide | −3.38 | 3 | 2.172 | GLY 1656, (H) H | O |
| | | | 1.944 | SER 6: H (HG) | O |
| | | | 1.753 | LYS1702: (H) HZ2 | O |
| Tamoxifen | −2 | 1 | 2.004 | SER 6: H (HG) | N |
| 1-(2-Hydroxyphenyl)-4-methylpentan-1-one | −4.7 | 3 | 2.223 | SER 6: H (HG) | O |
| | | | 2.098 | GLY 1656, (H) H | O |
| | | | 2.012 | SER 6: H (HG) | O |
| 2-[(3-Methylbutoxy)carbonyl] benzoic acid | −3.86 | 5 | 2.257 | SER 6: H (HG) | O |
| | | | 2.142 | GLY 1656, (H) H | O |
| | | | 2.070 | GLY 1656, (H) H | O |
| | | | 1.916 | SER 6: H (HG) | O |
| | | | 1.709 | LYS1702: (H) HZ2 | O |
| 4-Methylpentyl benzoate | −3.83 | 3 | 2.032 | GLY 1656, (H) H | O |
| | | | 1.776 | SER 6: H (HG) | O |
| | | | 1.677 | LYS1702: (H) HZ2 | O |
| 2-(5-Methylhexyl) benzoic acid | −3.7 | 1 | 2.066 | LEU1701: (H) H | O |
| 3-(Iminomethyl)-2,4-dimethylphenol | −3.6 | 3 | 2.477 | LYS1702: (H) HZ2 | N |
| | | | 2.099 | PRO9: (O) O | H |
| | | | 1.999 | LEU1701: (H) H | O |
| 3-Methylbutyl benzoate | −3.4 | 1 | 1.947 | LYS1702: (H) H | O |

Glide score, number of H-bond interactions, distance of H-bond interaction, and involved protein atom and ligand atom in interaction of isolated and standard drugs with BRCA1 protein obtained from docking studies.
### Table 4: Docking score and H-bond interaction of ligands with BRCA2 protein (3EU7).

| Ligand                                  | Glide score | Number of H-bonds | Distance (Å) | Protein atom       | Ligand atom |
|-----------------------------------------|-------------|--------------------|--------------|--------------------|--------------|
| Doxorubicin                             | −11.1       | 4                  | 2.043        | LYSI062: (H) HZ3   | O            |
|                                        |             |                    | 1.994        | ASPI122: (O) OD1   | H            |
|                                        |             |                    | 1.921        | ASPI125: (H) H     | O            |
|                                        |             |                    | 1.926        | ASPI125: (O) OD2   | H            |
|                                        |             |                    | 1.843        | ASPI122: (O) OD1   | H            |
| Tamoxifen                               | −5.9        | 2                  | 2.125        | ASPI122: (O) OD2   | H            |
|                                        |             |                    | 2.022        | ASPI122: (O) OD2   | H            |
| Letrozole                               | −3.0        | 2                  | 2.179        | VAL1969: (H) H    | N            |
|                                        |             |                    | 2.185        | HID1061: (H) HD1   | N            |
| Cyclophosphamide                       | −3.2        | 2                  | 2.211        | LYSI062: (H) HZ3   | O            |
|                                        |             |                    | 1.923        | GLU1018: (H) H    | O            |
| Paclitaxel                              | −2.9        | 4                  | 2.429        | LYSI062: (H) HZ3   | O            |
|                                        |             |                    | 1.933        | LYSI062: (H) HZ3   | O            |
|                                        |             |                    | 1.819        | GLY971: (O) O     | H            |
|                                        |             |                    | 1.408        | HID1061: (O) O    | H            |
| 1-(2-Hydroxyphenyl)-4-methylpentan-1-one| −4.5        | 3                  | 2.382        | GLY1166: (H) H    | O            |
|                                        |             |                    | 2.287        | ALA874: (H) H     | O            |
|                                        |             |                    | 1.850        | ALA874: (O) O     | H            |
| 4-Methylpentyl benzoate                | −3.8        | 2                  | 2.149        | ALA1063: (H) H    | O            |
|                                        |             |                    | 2.215        | LYSI062: (H) HZ2  | O            |
| 2-[(3-Methyloxy)carbonyl]benzoic acid  | −3.1        |                    |              |                    |              |

Glide score, number of H-bond interactions, distance of H-bond interaction, and involved protein atom and ligand atom in interaction of isolated and standard drugs with BRCA2 protein obtained from docking studies.

**Figure 2**: Close view of BRCA1 docked with (a) doxorubicin, (b) letrozole, (c) 1-(2-hydroxyphenyl)-4-methylpentan-1-one, and (d) 2-[(3-methyloxy)carbonyl]benzoic acid. Isolated compounds (green color ball stick mode) docked with target protein BRCA1 (stick mode) through hydrogen bond interaction (pink color dot).
The binding pocket of BRCA1 contains two chains with two fragments (BCRT1 and BCRT2). BRCA1 is interacting with protein c-terminal helicase 1. The highly conserved C-terminal BRCT repeats that function as a phosphoserine/phosphothreonine-binding module. Clapperton et al. [56] reported the X-ray crystal structure at a resolution of 1.85 Å of the BRCA1 tandem BRCT domains in complex with a phosphorylated peptide representing the minimal interacting region of the DEAH-box helicase BACH1. The structure revealed the determinants of this novel class of BRCA1 binding events. Transcription/antitumor protein BRCA2 contains two chains with a fragment c-terminal WD40 domain having residues 835–1186. The synonym is PALB2, Fanconi anemia group n protein. 19-meric peptides have been identified from BRCA2 protein. The second fragment interacts with PALB2 having residues 21–39. The early onset protein (BRCA2) is central to the repair of DNA damage. BRCA2 recruits recombinase RAD51 to sites of damage, regulates its assembly into nucleoprotein filaments, and thereby promotes homologous recombination. Localization of BRCA2 to nuclear foci requires its association with the partner and localizer of BRCA2 (PALB2), mutations which are associated with cancer predisposition, as well as subtype n of Fanconi anaemia. Oliver et al. [57] have determined the structure of the PALB2 carboxy-terminal beta-propeller domain in complex with a BRCA2 peptide.

The molecular docking insights provide isolated compounds and standard drugs were docked against the COX-1 and COX-2 proteins. The results of COX-1 docking showed, among 6 compounds, only 4 compounds were found to be docked firmly with the target protein. The docking score and the interaction of the compounds seem to be highly significant. 1-(2-Hydroxyphenyl)-4-methylpentan-1-one and 2-[3-(methylbutoxy) carboxyl] benzoic acid showed strong binding affinities with G score of −5.8 and −4.4, respectively. The G score of the compounds were found to be higher than the majority of the standard drugs used. However, indomethacin also showed good results (G score −6.67). The G score of the isolated compounds 2-(5-methylhexyl) benzoic acid and 3-(iminomethyl)-2,4-dimethylphenol were −3.43 and −3.23, respectively, whereas the G scores of the standard drugs such as aspirin, diclofenac, paracetamol, and morphine were −5.65, −3.77, −3.41, and −3.36, respectively (Table 5). The topmost interacted compounds against target proteins are showed in Figure 4. The binding of isolated compounds and standard drugs to the active sites of COX-2 protein is shown in Figure 5. The docking score and the interaction of the compounds were tabulated (Table 6). The G score of the compounds 2-[3-(methylbutoxy) carboxyl] benzoic acid and 1-(2-hydroxyphenyl)-4-methylpentan-1-one was −2.9 and −2.4. The G score of the standard drug diclofenac is −3.4.

The results of the COX-1 docking with the isolated compounds are found to be significant. The G score of the three isolated compounds (−3.23 to −5.28) was higher than standard drugs such as diclofenac, paracetamol, and morphine (−3.77, −3.41, and −3.36). The hydrogen bond interaction of 2-[3-(methylbutoxy) carboxyl] benzoic acid and diclofenac seems to be similar. 1-(2-Hydroxyphenyl)-4-methylpentan-1-one formed two hydrogen bonds with the ASN 375: (H) H and ASN 375: (O) O residues of COX-1 and 2-[3-(methylbutoxy) carboxyl] benzoic acid formed three hydrogen bonds with the ARG 374: (H) HH2I, ARG
Table 5: Docking score and H-bond interaction of ligands with COX-1 protein (1EQH).

| Ligand                                   | $G'$ score | Number of H-bonds | Distance (Å) | Protein atom | Ligand atom |
|------------------------------------------|------------|--------------------|--------------|--------------|-------------|
| Indomethacin                             | −6.67      | 3                  | 2.230        | ARG 374: (H) HH22 | O           |
|                                          |            |                    | 2.271        | ARG 374: (H) HH21 | O           |
|                                          |            |                    | 1.986        | ARG 374: (H) HE  | O           |
| Aspirin                                  | −5.65      | 5                  | 2.066        | ARG 374: (H) HH22 | O           |
|                                          |            |                    | 2.043        | ASN 375: (H) H   | O           |
|                                          |            |                    | 2.199        | ARG 374: (H) HE  | O           |
|                                          |            |                    | 1.857        | ARG 374: (H) HH12| O           |
|                                          |            |                    | 1.781        | ARG 374: (H) HH21| O           |
| Diclofenac                               | −3.77      | 3                  | 2.238        | ARG 374: (H) HH22 | O           |
|                                          |            |                    | 2.017        | ASN 375: (H) H   | O           |
|                                          |            |                    | 1.824        | ARG 374: (H) HH22| O           |
| Paracetamol                              | −3.41      | 2                  | 2.139        | ARG 374: (H) HH21| O           |
|                                          |            |                    | 1.936        | GLY225: (O) O    | H           |
| Morphine                                 | −3.36      | 1                  | 1.984        | ARG 374: (H) HH22| O           |
| 1-(2-Hydroxyphenyl)-4-methylpentan-1-one | −5.28      | 2                  | 1.964        | ASN 375: (H) H   | O           |
|                                          |            |                    | 1.734        | ASN 375: (O) O   | H           |
| 2-[(3-Methylbutoxy)carbonyl] benzoic acid| −4.4       | 3                  | 2.106        | ARG 374: (H) HH21| O           |
|                                          |            |                    | 1.896        | ARG 374: (H) HH12| O           |
|                                          |            |                    | 1.979        | ASN 375: (H) H   | O           |
| 2-(5-Methylhexyl) benzoic acid           | −3.43      | 1                  | 2.044        | ASN 375: (H) H   | O           |
| 3-(Iminomethyl)-2,4-dimethylphenol       | −3.23      | 2                  | 2.226        | ASN 375: (H) H   | O           |
|                                          |            |                    | 1.700        | ASN 375: (O) O   | O           |

Glide score, number of H-bond interactions, distance of H-bond interaction, and involved protein atom and ligand atom in interaction of isolated and standard drugs with COX-1 protein obtained from docking studies.

Figure 4: Close view of COX-1 docked with (a) indomethacin, (b) aspirin, (c) 1-(2-hydroxyphenyl)-4-methylpentan-1-one, and (d) 2-[(3-methylbutoxy)carbonyl]benzoic acid. Isolated compounds (green color ball stick mode) docked with target protein COX-1 (stick mode) through hydrogen bond interaction (pink color dot).
Figure 5: Close view of COX-2 docked with (a) diclofenac, (b) indomethacin, (c) 2-[(3-methylbutoxy) carbonyl] benzoic acid, and (d) 1-(2-hydroxyphenyl)-4-methylpentan-1-one. Isolated compounds (green color ball stick mode) docked with target protein COX-2 (stick mode) through hydrogen bond interaction (pink color dot).

The docking results of isolated compounds with COX-2 are significant when compared with the standard drugs. The G score of the compounds ranged between $-2.9$ and $-0.4$; 2-[(3-methylbutoxy) carbonyl] benzoic acid had the highest G score in the isolated compounds, bound with HID 228: (H) HDI, LYS 543: (H) HZI, and LYS 543: (H) HZI residues of the COX-2 protein. The binding residues (LYS 543: (H) HZ3, LYS 543: (H) HZ2, and THR 547: (H) HGI) of the diclofenac were also similar to 2-[(3-methylbutoxy) carbonyl] benzoic acid. Recent studies have shown that stellatin has COX-1 and COX-2 inhibitory activities which was isolated from *Dysophylla stellata*. Docking study revealed the binding orientations of stellatin and its derivatives into COX-1 and COX-2 and thereby helps to design potent inhibitors [58].

Olgen et al. [59] reported the COX inhibitory activities of indomethacin derivatives (N-substituted indole-2-carboxylic acid esters). All the derivatives were shown to be docked at the site where intact flurbiprofen was embedded for COX-1 and s-58 (1-phenylsulphonamide-3-trifluoromethyl-5-para-bromophenylpyrazole) for COX-2. Three series of spiro derivatives have been synthesized and docked to COX-2 by Amin et al. [60]. The results showed nearest value of indomethacin. Abdel-Aziz et al. [61] designed a group of cyclic imides (1–13) and evaluated its selective COX-2 inhibition. The molecular docking study showed that the CH$_2$O substituents of 5b were inserted firmly to COX-2, where the O-atoms of such group underwent a H-bonding interaction with HIS 90 (2.43, 2.83 Å), ARG 513 (2.89 Å), and TYR 355 (3.34 Å). This revealed a similar binding mode to SC-558, a selective COX-2 inhibitor. Basele and coworkers [62] have synthesised 14 sulfonilamidothiopyrimidone derivatives. Compounds 2–5 were able to fit into the active site of COX-2 with highest scores and interaction energies. Furthermore, compound 2, which showed an inhibition of around 50% on PGE2 production, was best scored. El-Sayed et al. [63] designed and synthesized new arylhydrazon e derivatives and a series of 1,5-diphenyl pyrazoles from 1-(4-chlorophenyl)-4,4,4-trifluorobutane-1,3-dione 1. The designed compounds docked into the COX-2. Docking study of the synthesized compounds 2f, 6a, and 6d into COX-2 revealed a similar binding mode to SC-558, a selective COX-2 inhibitor.

**Synonym of prostaglandin H2 synthase-1 is COX-1.** Non-steroidal anti-inflammatory drugs block prostanoid biosynthesis by inhibiting prostaglandin H (2) synthase. Selinsky et al. [64] reported the crystal structure of COX-1 complex with the inhibitors ibuprofen, methyl flurbiprofen, flurbiprofen, and alclofenac at resolutions ranging from 2.6 to 2.75 Å. These structures allow direct comparison of enzyme complexes with reversible competitive inhibitors (ibuprofen and methyl flurbiprofen) and slow tight-binding inhibitors (alclofenac and flurbiprofen). All the inhibitors bind to the same site and adopt similar conformations. In all four complexes, the enzyme structure is essentially unchanged, exhibiting only minimal differences in the inhibitor binding site. The different apparent modes of NSAID binding may result from differences in the speed and efficiency with which inhibitors can disturb the hydrogen bonding network around Arg-120.
Table 6: Docking score and H-bond interaction of ligands with COX-2 protein (3LN1).

| Ligand                        | $G$ score | Number of H-bonds | Distance (Å) | Protein atom             | Ligand atom |
|-------------------------------|-----------|-------------------|--------------|--------------------------|--------------|
| Diclofenac                    | −3.4      | 3                 | 2.151        | LYSS543: (H) HZ3          | (O) O3       |
|                               |           |                   | 2.121        | LYSS543: (H) HZ2          | O            |
|                               |           |                   | 1.802        | THR547: (H) HG1           | (O) O3       |
| Indomethacin                  | −3.2      | 2                 | 2.041        | ARG297: (H) H            | O            |
|                               |           |                   | 1.767        | LYSS543: (H) HZ2          | (O) O4       |
| Aspirin                       | −2.8      | 3                 | 2.112        | LYS S43: (H) HZ3          | (O) O20      |
|                               |           |                   | 2.140        | THR547: (H) HG1           | (O) O20      |
|                               |           |                   | 2.049        | ARG297: (H) H21           | (O) O3       |
| Paracetamol                   | −2.4      | 3                 | 2.383        | GLU539: (O) OE2           | H            |
|                               |           |                   | 2.264        | TRP531: (H) HE1           | O            |
|                               |           |                   | 2.014        | GLU539: (O) OE1           | H            |
| Morphine                      | −1.0      | 5                 | 2.471        | ARG297: (H) HE            | (O) O2       |
|                               |           |                   | 2.249        | ASN556: (O) OD1           | (H) H38      |
|                               |           |                   | 2.025        | ARG297: (H) HH21          | (O) O21      |
|                               |           |                   | 1.989        | ARG297: (H) HH21          | (O) O2       |
|                               |           |                   | 1.974        | ARG297: (H) HH22          | (O) O3       |
| 2-[(3-Methylbutoxy)carbonyl] benzoic acid | −2.9 | 3 | 2.115 | HID228: (H) HD1 | (O) O8 |
|                               |           |                   | 2.065        | LYS S43: (H) HZ1          | (O) O2       |
|                               |           |                   | 1.774        | LYS S43: (H) HZ3          | (O) O13      |
| 1-(2-Hydroxyphenyl)-4-methylpentan-1-one | −2.4 | 2 | 2.085 | TRP531: (H) HE1 | (O) O7 |
|                               |           |                   | 1.726        | ASP348: (O) OD1           | H            |
| 3-Methylbutyl benzoate         | −2.1      | 1                 | 1.898        | THR547: (H) HG1           | O            |
| 4-Methylpentyl benzoate        | −2.1      | 2                 | 2.139        | LYS543: (H) HZ2           | (O) O35      |
|                               |           |                   | 2.033        | THR547: (H) HG1           | O            |
| 2-(5-Methylhexyl) benzoic acid | −1.3      | 1                 | 2.156        | TRP531: (H) HE1           | O            |
| 3-(Iminomethyl)-2,4-dimethylphenol | −0.4 | 1 | 2.171 | ASN546: (H) HD21 | O |

Glidescore, number of H-bond interactions, distance of H-bond interaction, and involved protein atom and ligand atom in interaction of isolated and standard drugs with COX-2 protein obtained from docking studies.

and Tyr-355. Chou [65] studied the various methods adopted to understand the molecular mechanism of proteins and conduct structure based drug design by timely using the updated information of newly found sequences. He has also reported three main strategies developed in structural bioinformatics, that is, pure energetic approach, heuristic approach, and homology modeling approach, as well as their underlying principles, in a review. These approaches help to understand the action mechanisms of proteins and stimulating the course of drug discovery. In the literature, the binding pocket of a protein receptor to a ligand is usually defined by those residues that have at least one heavy atom (i.e., an atom other than hydrogen) with a distance < 5 Å from a heavy atom of the ligand. Such a criterion was originally used to define the binding pocket of ATP in the Cdk5-NckSa complex [66] and has later proved quite useful in identifying functional domains and stimulating the relevant truncation experiments. The similar approach has also been used to define the binding pockets of many other receptor-ligand interactions important for drug design.

Computational molecular docking is a useful tool for investigating the interaction of a target protein receptor with its ligand and revealing their binding mechanism as demonstrated by various studies [22–27]. In this study well known docking program Glide module is used to dock the isolated compounds of R. fairholmianus root acetone and the standard drugs to the active pockets of BRCA and COX target proteins to study the mode of interaction and inhibitory properties. Many marvelous biological functions in proteins and DNA and their profound dynamic mechanisms, such as switch between active and inactive states [67], cooperative effects [68], and allosteric transition [69], can be revealed by studying their internal motions [70]. Likewise, to really understand the action mechanism between a drug compound and its target protein, we should consider not only the static binding structure but also the dynamical information obtained by simulating their internal motions or dynamic process. We will consider this in our future studies.

4. Conclusions

The present study describes the bioactivity guided isolation, structure elucidation and antioxidant activities, and molecular docking of 6 compounds: 1-(2-hydroxyphenyl)-4-methylpentan-1-one (1), cis-2-(isopentoxycarbonyl) benzoic acid (2), 2-(5-methylhexyl) benzoic acid (3), 4-methylpentyl benzoate (4), 3-(iminomethyl)-2,4-dimethylphenol (5), and isopentyl benzoate or 3-methyl benzoate (6) from the root acetone extract of R. fairholmianus. No previous reports are available on the compound isolation and other bioactivity
studies of this plant. The investigation describes the isolated compounds from acetone extract of *R. fairholmianus* root docked to the active pockets of BRCA and COX proteins to predict analogous binding mode of the BRCA and COX inhibitors. The results revealed that the compounds were docked more firmly and inhibited the breast cancer related BRCA1 and BRCA2 oncoproteins and COX-2 and COX-1 inflammatory proteins. Among the 6 compounds, 1-(2-hydroxyphenyl)-4-methylpentan-1-one and 2-[(3-methylbutoxy) carbonyl] benzoic acid were found to be more active in inhibiting BRCA and COX proteins, which also revealed the better results for antioxidant assays. Therefore, these compounds may be considered as the lead compounds for further development of therapeutic drugs.

**Conflict of Interests**

The authors declare that there is no conflict of interests.

**References**

[1] C. E. Finn, “*Rubus* spp., blackberry,” in *The Encyclopedia of Fruits and Nuts*, J. Janick and R. E. Paull, Eds., pp. 348–351, CABI, Cambridge, Mass, USA, 2008.

[2] A. V. Patel, J. Rojas-Vera, and C. G. Dacke, “Therapeutic constituents and actions of *Rubus* species,” *Current Medicinal Chemistry*, vol. 11, no. 11, pp. 1501–1512, 2004.

[3] N. J. Das, S. P. Saikia, S. Sarkar, and K. Devi, “Medicinal plants of north kamrup district of Assam used in primary health care system,” *International Journal of Traditional Knowledge*, vol. 5, no. 22, pp. 489–493, 2006.

[4] J. Barukial and J. N. Sarmah, “Ethnomedicinal plants used by the people of Golaghat district, Assam, India,” *International Journal of Medicinal and Aromatic Plant*, vol. 1, no. 3, pp. 203–211, 2011.

[5] B. P. George, T. Parimelazhagan, and R. Chandran, “Evaluation of total phenolic content, antioxidant and analgesic potential of Rubus fairholmianus gard,” *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 5, no. 3, pp. 484–488, 2013.

[6] B. P. George, T. Parimelazhagan, and R. Chandran, “Anti-inflammatory and wound healing properties of *Rubus fairholmianus* Gard. root—an in vivo study,” *Industrial Crops and Products*, vol. 54, pp. 216–225, 2014.

[7] B. P. George, T. Parimelazhagan, and S. Saravanaan, “Anti-inflammatory, analgesic and antipyretic activities of *Rubus ellipticus* smith. leaf methanol extract,” *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 5, no. 2, pp. 220–224, 2013.

[8] B. P. George, T. Parimelazhagan, S. Saravanaan, and R. Chandran, “Anti-inflammatory, analgesic and antipyretic properties of *Rubus niveus* Thunb., root acetone extract,” *Pharmacologia*, vol. 4, no. 3, pp. 228–235, 2013.

[9] B. P. George, T. Parimelazhagan, T. K. Yamini, and T. Sajeeesh, “Antitumor and wound healing properties of *Rubus ellipticus* Smith,” *Journal of Acupuncture and Meridian Studies*, 2013.

[10] K. R. Määtä-Riihinen, A. Kamal-Eldin, and A. R. Törrönen, “Identification and quantification of phenolic compounds in berries of Fragaria and *Rubus* species (family rosaceae),” *Journal of Agricultural and Food Chemistry*, vol. 52, no. 20, pp. 6178–6187, 2004.

[11] C. Mertz, V. Cheynier, Z. Günata, and P. Brat, “Analysis of phenolic compounds in two blackberry species (*Rubus glaucus* and *Rubus adenotruchus*) by high-performance liquid chromatography with diode array detection and electro spray ion trap mass spectrometry,” *Journal of Agricultural and Food Chemistry*, vol. 55, no. 21, pp. 8616–8624, 2007.

[12] G. E. Pantelidis, M. Vasilakakis, G. A. Manganaris, and G. Diamantidis, “Antioxidant capacity, phenol, anthocyanin and ascorbic acid contents in raspberries, blackberries, red currants, gooseberries and Cornelian cherries,” *Food Chemistry*, vol. 102, no. 3, pp. 777–783, 2007.

[13] J. Reyes-Carmona, G. Y. Yousef, R. A. Martínez-Peniche, and M. A. Lila, “Antioxidant capacity of fruit extracts of blackberry (*Rubus sp.*) produced in different climatic regions,” *Journal of Food Science*, vol. 70, no. 7, pp. S497–S503, 2005.

[14] S. Y. Wang and H. Lin, “Antioxidant activity in fruits and leaves of blackberry, raspberry, and strawberry varies with cultivar and developmental stage,” *Journal of Agricultural and Food Chemistry*, vol. 48, no. 2, pp. 140–146, 2000.

[15] A. Szajdek and E. J. Borowska, “Bioactive compounds and health-promoting properties of berry fruits: a review,” *Plant Foods for Human Nutrition*, vol. 63, no. 4, pp. 147–156, 2008.

[16] M. Laguerre, J. Lecomte, and P. Villeneuve, “Evaluation of the ability of antioxidants to counteract lipid oxidation: existing methods, new trends and challenges,” *Progress in Lipid Research*, vol. 46, no. 5, pp. 244–282, 2007.

[17] J. Reyes-Carmona, G. Y. Yousef, R. A. Martínez-Peniche, and M. A. Lila, “Antioxidant capacity of fruit extracts of blackberry (*Rubus sp.*) produced in different climatic regions,” *Journal of Food Science*, vol. 70, no. 7, pp. S497–S503, 2005.

[18] W. Zheng and S. Y. Wang, “Antioxidant activity and phenolic compounds in selected herbs,” *Journal of Agricultural and Food Chemistry*, vol. 49, no. 11, pp. 5165–5170, 2001.

[19] V. Sharma, H. V. Kumar, and L. J. M. Rao, “Influence of milk and sugar on antioxidant potential of black tea,” *Fod Research International*, vol. 41, no. 2, pp. 124–129, 2008.

[20] M. S. Blois, “Antioxidant determinations by the use of a stable free radical,” *Nature*, vol. 181, no. 4617, pp. 1199–1200, 1958.

[21] R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang, and C. Rice-Evans, “Antioxidant activity applying an improved ABTS radical cation decolorization assay,” *Free Radical Biology and Medicine*, vol. 26, no. 9–10, pp. 1231–1237, 1999.

[22] K. C. Chou, D. Q. Wei, and W. Z. Zhong, “Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS,” *Biochemical and Biophysical Research Communications*, vol. 308, no. 1, pp. 148–151, 2003.

[23] Q. Du, S. Wang, D. Wei, S. Sirois, and K. Chou, “Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase,” *Analytical Biochemistry*, vol. 337, no. 2, pp. 262–270, 2005.

[24] L. Cai, Y. Wang, J. Wang, and K. Chou, “Identification of proteins interacting with human SARS-CoV1 in vivo,” *Foods for Human Nutrition*, vol. 63, no. 4, pp. 147–156, 2008.

[25] Q. H. Liao, Q. Z. Gao, J. Wei, and K. C. Chou, “Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidemial growth factor receptor (EGFR),” *Medicinal Chemistry*, vol. 7, no. 1, pp. 24–31, 2011.

[26] Y. Ma, S. Q. Wang, W. R. Xu, R. L. Wang, and K. C. Chou, “Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hipping approach,” *PLoS ONE*, vol. 7, no. 6, Article ID e38546, 2012.
[57] A. W. Oliver, S. Swift, C. J. Lord, A. Ashworth, and L. H. Pearl, "Structural basis for recruitment of BRCA2 by PALB2," *EMBO Reports*, vol. 10, no. 9, pp. 990–996, 2009.

[58] R. Gautam, S. M. Jachak, V. Kumar, and C. G. Mohan, "Synthesis, biological evaluation and molecular docking studies of stellatin derivatives as cyclooxygenase (COX-1, COX-2) inhibitors and anti-inflammatory agents," *Bioorganic and Medicinal Chemistry Letters*, vol. 21, no. 6, pp. 1612–1616, 2011.

[59] S. Olgen, E. Akaho, and D. Nebioglu, "Synthesis and receptor docking studies of N-substituted indole-2-carboxylic acid esters as a search for COX-2 selective enzyme inhibitors," *European Journal of Medicinal Chemistry*, vol. 36, no. 9, pp. 747–770, 2001.

[60] K. M. Amin, M. M. Kamel, M. M. Anwar, M. Khedr, and Y. M. Syam, "Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1'-cyclooxan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents," *European Journal of Medicinal Chemistry*, vol. 45, no. 6, pp. 2117–2131, 2010.

[61] A. A.-. Abdel-Aziz, K. E. H. Eltahir, and Y. A. Asiri, "Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1. Molecular docking study," *European Journal of Medicinal Chemistry*, vol. 46, no. 5, pp. 1648–1655, 2011.

[62] L. Basile, S. Álvarez, A. Blanco et al., "Sulfonilamidothiopyrimidine and thiopyrimidine derivatives as selective COX-2 inhibitors: synthesis, biological evaluation, and docking studies," *European Journal of Medicinal Chemistry*, vol. 57, pp. 149–161, 2012.

[63] M. A.-A. El-Sayed, N. I. Abdel-Aziz, A. A.-M. Abdel-Aziz, A. S. El-Azab, Y. A. Asiri, and K. E. H. Eltahir, "Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: molecular docking study," *Bioorganic & Medicinal Chemistry*, vol. 19, no. 11, pp. 3416–3424, 2011.

[64] B. S. Selinsky, K. Gupta, C. T. Sharkey, and P. J. Loll, "Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations," *Biochemistry*, vol. 40, no. 17, pp. 5172–5180, 2001.

[65] K. Chou, "Low-frequency resonance and cooperativity of hemoglobin," *Trends in Biochemical Sciences*, vol. 14, no. 6, pp. 212–213, 1989.

[66] J. F. Wang and K. C. Chou, "Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations," *Biochemical and Biophysical Research Communications*, vol. 390, no. 3, pp. 608–612, 2009.

[67] K. C. Chou, "Low-frequency resonance and cooperativity of hemoglobin," *Trends in Biochemical Sciences*, vol. 14, no. 6, pp. 212–213, 1989.

[68] J. R. Schnell and J. J. Chou, "Structure and mechanism of the M2 proton channel of influenza A virus," *Nature*, vol. 451, no. 7178, pp. 591–595, 2008.

[69] K. Chou, "Low-frequency collective motion in biomacromolecules and its biological functions," *Biophysical Chemistry*, vol. 30, no. 1, pp. 3–48, 1988.